Here's why I can't wait to buy Chemist Warehouse shares

Chemist Warehouse would tick all my boxes for a great investment.

| More on:
Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the biggest pieces of ASX news this week was the revelation that Chemist Warehouse shares might, at long last, be coming to the Australian stock market.

As we covered earlier this week, rumours are abounding that Chemist Warehouse might make its long-awaited ASX debut through some kind of 'reverse-merger' with ASX 300 healthcare stock Sigma Healthcare Ltd (ASX: SIG).

Sigma shares were quickly halted from trading amid these rumours, with the company confirming that "an announcement relating to a potential material transaction" is on the way. The shares have reportedly been halted until at least next week to "ensure the market is not trading on an uninformed basis while those discussions are ongoing".

So we don't yet know if Chemist Warehouse is indeed coming to the public markets. But I'm excited anyway. That's because Chemist Warehouse — if it does eventually list on the ASX — is a company that ticks almost all of my boxes as a potential investment.

Why am I keen to buy Chemist Warehouse shares?

Chances are most of us have visited a Chemist Warehouse somewhat recently. After all, this is a pharmacy chain that, according to a recent analysis from EY, "now commands over 50% market share in Australia".

Chemist Warehouse (at least in its current form) was founded back in 1993. So this is quite an accomplishment. Its controversial (yet evidently lucrative) business strategy of sidestepping Australia's strict pharmaceutical regulations that limit pharmacy proliferation has proved to be a winner.

My favourite investments usually have at least some of the following characteristics

  • a market leader in its industry
  • indication of the presence of a strong economic moat
  • operating in a defensive sector that is resistant to recessions and inflation

Chemist Warehouse seems to tick all three boxes.

It's clear that the company commands a leading position in the pharmaceutical industry if EY's analysis is to be believed.

Chemist Warehouse has strong brand power, as well as an obvious pricing advantage. Both of these moats have arguably allowed the company to expand at the expense of competitors.

And pharmaceuticals and medicines are highly defensive markets. When most of us are sick, we buy the medicines and pharmaceuticals that help us ride it out, regardless of economic conditions.

Private companies and public knowledge

Of course, I'll be doing some due diligence before I actually pick up the shares. Even now, Chemist Warehouse remains a private company. This means that details such as internal operations, financials and other information that public companies have to disclose remain unavailable to the public.

I'll want to get a good look at this information before buying up shares. I'll also want to buy the company at a price that makes sense. Not on whatever it trades at when it first lists.

But even so, I'll be excited to pick up some shares if and when the company eventually joins the ASX. Provided there are no red flags, of course.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 3 April 2025

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this fund manager is all in on Pro Medicus shares and recently increased his bet

This high-flying stock has suffered from turbulence.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Why I'm taking a closer look at ResMed shares

The ResMed share price hasn’t escaped recent market volatility. Is it time to buy?

Read more »

Health professional working on his laptop.
Healthcare Shares

Trump 2.0: Macquarie's take on the winners and losers in Australian healthcare

Let's see what the broker is saying about these healthcare stocks.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Own CSL shares? You're getting a dividend paycheque today

There's a silver lining to today's sell-off.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

How this Trump appointee could pressure the CSL share price

A leading expert believes Donald Trump isn’t doing CSL shareholders any favours.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Top broker says Mesoblast shares can rocket 100%

Big returns could be on offer from this biotech according to Bell Potter.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Healthcare Shares

Forget Trump! Here are 3 reasons to buy this $32 billion ASX 200 healthcare share today

A leading expert forecasts more growth ahead for this $32 billion ASX 200 healthcare company.

Read more »

A scientist examining test results.
Healthcare Shares

1 ASX dividend stock down 43% I'd buy right now

This business could provide both dividends and growing, defensive earnings.

Read more »